Trading Systems Reacting to (INBX) Volatility
This article analyzes Inhibrx Biosciences Inc (INBX) volatility using AI models, highlighting weak near-term sentiment despite strong mid and long-term outlooks. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for different risk profiles. The analysis also provides multi-timeframe signal analysis, including support and resistance levels.
Inhibrx Biosciences, Inc. $INBX Shares Sold by Credit Industriel ET Commercial
Credit Industriel ET Commercial significantly reduced its stake in Inhibrx Biosciences (NASDAQ:INBX) by 54.9% in the third quarter, now holding 28,958 shares valued at approximately $975,000. Despite the company beating Q3 EPS consensus, analysts maintain a "Reduce" average rating on the stock, with shares recently down 7.7% and opening at $75.80. Other institutional investors have shown mixed activity, with some increasing and others reducing their positions in INBX.
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 6.8% - Here's What Happened
Inhibrx Biosciences (NASDAQ:INBX) saw its shares drop by 6.8% on Friday, trading as low as $76.01 with a significantly reduced volume of 97,486 shares. The company, a clinical-stage biotech developing protein therapeutics, has a consensus "Reduce" rating from analysts, with a negative P/E ratio but strong liquidity. Institutional investors have recently made adjustments to their holdings in the stock.
How Inhibrx Biosciences Inc Com (INBX) Affects Rotational Strategy Timing
This article analyzes Inhibrx Biosciences Inc Com (INBX) and its impact on rotational strategy timing, highlighting strong sentiment across all time horizons. It details institutional trading strategies, including long, momentum breakout, and risk hedging, with specific entry points, targets, and stop losses. The analysis also provides multi-timeframe signal strengths with support and resistance levels.
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 10.2% - Still a Buy?
Shares of Inhibrx Biosciences (INBX) surged 10.2% to $84.05 on Monday, though this occurred on low trading volume. Despite beating quarterly EPS estimates, the company holds an average analyst rating of "Reduce," with two Holds and one Sell. Inhibrx maintains strong liquidity and significant institutional ownership, but analysts forecast negative EPS for the current fiscal year.
Commit To Purchase Inhibrx Biosciences At $50, Earn 16.7% Annualized Using Options
This article discusses an options strategy for investors interested in Inhibrx Biosciences Inc (INBX) but cautious about its current market price. By selling a January 2027 put option at a $50 strike price, investors could earn an annualized return of 16.7%. This strategy offers a substantial premium if the stock does not fall significantly, but obligates the investor to purchase shares at $50 if the option is exercised due to a price drop.
Inhibrx Biosciences Reports Promising Q3 2025 Results
The provided content is empty, so a summary cannot be generated.
Responsive Playbooks and the INBX Inflection
This article analyzes Inhibrx Biosciences Inc (INBX) with a focus on its current weak near and mid-term sentiment, contrasting it with a strong long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, highlighting a significant 106.9:1 risk-reward setup targeting a 30.4% gain.
Short Interest in Inhibrx Biosciences, Inc. (NASDAQ:INBX) Rises By 63.1%
Short interest in Inhibrx Biosciences, Inc. (NASDAQ:INBX) significantly increased by 63.1% in December, reaching 1,712,725 shares. This represents about 11.8% of the company's shares being short sold, with a days-to-cover ratio of 6.2 days. Despite beating quarterly EPS estimates, the stock's market performance showed a 5.4% decline, and Wall Street analysts currently hold a "Reduce" consensus rating.
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.5% - What's Next?
Inhibrx Biosciences' (NASDAQ:INBX) stock fell by 6.5% to $71.04 in mid-day trading on Tuesday, with trading volume significantly lower than average. Analyst sentiment remains weak for the company, holding a consensus "Reduce" rating. Despite a negative P/E ratio, the company recently beat EPS estimates, and institutional investors own a substantial 82.46% of its shares.
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Sees Large Decline in Short Interest
Inhibrx Biosciences, Inc. (NASDAQ:INBX) experienced a significant 20.5% decline in short interest during December, totaling 1,049,942 shares as of December 15th. This reduction brings the days-to-cover ratio to 5.3 days, with 7.2% of the company's shares currently short sold. Additionally, a major shareholder, Global Investors Lp Viking, sold a substantial portion of its holdings, and institutional investors now hold 82.46% of the stock.
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
Inhibrx Biosciences Inc. is progressing its primary oncology programs, INBRX-106 and ozekibart (INBRX-109), both designed to activate the immune system and target tumor cell death. The company expects multiple data readouts in 2026 for its Phase 2/3 trial of INBRX-106 in combination with Keytruda for head and neck squamous cell carcinoma and non-small cell lung cancer, as well as progression-free survival data for ozekibart in colorectal cancer. Enrollment for these trials is nearing completion, with results anticipated to assess sustained clinical benefit.
How (INBX) Movements Inform Risk Allocation Models
This article analyzes Inhibrx Biosciences Inc (INBX) stock movements, highlighting a weak near-term sentiment but strong long-term outlook. It presents three AI-generated trading strategies tailored for different risk profiles, along with multi-timeframe signal analysis and key levels. The piece emphasizes the importance of understanding INBX movements for risk allocation models.
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates
Inhibrx Biosciences (INBX) has updated investors on its oncology pipeline, with progress in INBRX-106 combo trials and ozekibart studies, leading to significant share price appreciation. Despite strong market momentum and a 498.63% one-year total shareholder return, the company's valuation presents an aggressive premium with a price-to-book ratio of 32.8x. This suggests investors are heavily anticipating future pipeline success rather than current fundamentals, contrasting sharply with industry averages.
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences announced updates on its INBRX-106 and ozekibart (INBRX-109) programs. The company expects to complete enrollment for the randomized Phase 2 portion of the INBRX-106 clinical trial for HNSCC in Q1 2026 and anticipates mature data for both HNSCC and NSCLC in H2 2026. For ozekibart, Inhibrx completed enrollment for colorectal cancer expansion cohorts and expects to complete enrollment for Ewing sarcoma in Q2 2026, with plans to discuss accelerated approval with the FDA in H2 2026 if trends continue.
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates
This article assesses Inhibrx Biosciences (INBX) valuation after recent oncology pipeline updates, including progress in INBRX-106 combo trials and ozekibart studies. Despite a significant year-to-date share price return of 444.85%, the company's price-to-book ratio of 32.8x suggests an aggressive valuation, far exceeding industry averages, and implying that the market is heavily anticipating future pipeline success rather than current fundamentals. The analysis highlights that while the company shows bullish momentum, its reliance on early-stage assets and ongoing losses present considerable risks.
Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures
Citizens has reiterated its Market Perform rating on Inhibrx Biosciences (NASDAQ:INBX) due to concerns over limited data disclosures and lack of management communication, despite the stock's significant gains over the past year. The firm questions the durability and strength of treatment responses in its clinical programs, particularly for INBRX-109, with mature progression-free survival data expected in Q2 2026. This assessment comes amidst other positive developments, including positive topline results for ozekibart and progress in the INBRX-106 clinical trial.
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences, Inc. announced updates on its INBRX-106 and ozekibart (INBRX-109) programs. The company has recruited 46 of 60 patients for the Phase 2 portion of the INBRX-106 trial for HNSCC, expecting to complete enrollment in Q1 2026, and completed enrollment for its NSCLC trial in November 2025. For ozekibart, enrollment for colorectal cancer patients was completed in late October 2025, and enrollment for Ewing sarcoma is expected to complete in Q2 2026, with plans to discuss accelerated approval with the FDA in H2 2026.
Inhibrx Biosciences Provides Updates on Clinical Trials
Inhibrx Biosciences announced updates on its INBRX-106 and ozekibart clinical trials on December 16, 2025. The INBRX-106 Phase 2 trial for HNSCC has recruited 46 of 60 patients, and the NSCLC trial with Keytruda completed enrollment of 34 patients, with efficacy data expected in late 2026. Separately, the ozekibart trial for colorectal cancer finished enrolling 44 patients, and an FDA meeting for the Ewing sarcoma trial is scheduled for late 2026.
Understanding Momentum Shifts in (INBX)
This article analyzes momentum shifts for Inhibrx Biosciences Inc Com (NASDAQ: INBX), noting weak near-term sentiment but prevailing positive sentiment overall. It provides AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies. The analysis highlights key support and resistance levels across near-term, mid-term, and long-term horizons.
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX
Mark Asset Management LP has acquired a new stake of 17,000 shares in Inhibrx Biosciences, Inc. (NASDAQ:INBX) valued at approximately $243,000, contributing to the 82.46% institutional ownership of the company. Despite weak analyst sentiment with a consensus "Reduce" rating, the company recently beat EPS expectations. The stock shows a market capitalization of $1.20 billion and has experienced significant price fluctuations over the past 12 months.
Inhibrx Biosciences advances sarcoma research with ozekibart trial results
Inhibrx Biosciences has announced significant developments in their sarcoma research, specifically concerning the ozekibart (INBRX 109) trial for chondrosarcoma. This advancement underlines the company's continuous efforts in oncology, building on previous successes in glioblastoma treatment. Inhibrx is further cementing its commitment to rare cancer therapies through strategic sponsorships and community engagement.
Inhibrx Biosciences, Inc. $INBX Shares Acquired by Kennedy Capital Management LLC
Kennedy Capital Management LLC increased its holding in Inhibrx Biosciences (NASDAQ:INBX) by 7.5% in the second quarter of 2025, acquiring 12,342 additional shares for a total of 177,318 shares valued at $2.53 million. Despite this, the stock carries mixed-to-negative analyst ratings ("Reduce" average) and has seen a major insider sell-off of 350,000 shares by Global Investors LP Viking. The company reports a negative trailing P/E of -8.93 but strong financial health with a quick ratio of 4.49, and its stock is currently trading near its 52-week high.
Inhibrx Biosciences stock hits all-time high at 87.89 USD
Inhibrx Biosciences stock reached an all-time high of $87.37, reflecting a 449.4% gain over the past year due to investor confidence. This surge follows positive clinical trial results for its experimental cancer drug, ozekibart, and strong market enthusiasm despite noted overvaluation and challenging gross profit margins, according to InvestingPro analysis.
Inhibrx Biosciences stock hits all-time high at 87.4 USD
Inhibrx Biosciences Inc. (INBX) stock price reached an all-time high of $87.40, marking a significant 1-year increase of 464.8%. Despite being overbought and overvalued according to InvestingPro data, the company also reported positive results from its registrational trial for the cancer drug ozekibart, significantly reducing disease progression in chondrosarcoma patients. Citizens maintains a "Market Perform" rating, acknowledging progress while suggesting a fair valuation.
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Biosciences, Inc. will host a live webcast on October 23, 2025, to present topline results from its registrational ChonDRAgon study of ozekibart (INBRX-109) in chondrosarcoma. The company will also provide updates on ongoing expansion trials for ozekibart in combination therapies for colorectal cancer and Ewing sarcoma. Ozekibart has received FDA Fast Track and orphan drug designations for chondrosarcoma.
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News
Inhibrx Biosciences' stock (INBX) surged dramatically following positive Phase 2 trial results for its drug ozekibart in advanced chondrosarcoma, a rare bone cancer with no approved systemic therapies. The drug significantly extended progression-free survival and showed promising results in other difficult-to-treat cancers, leading to plans for a Biologics License Application by Q2 2026. This breakthrough has generated significant investor interest and market volatility for the company.
Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory
Inhibrx Biosciences' stock surged by 61% following positive Phase II results for its drug ozekibart in treating chondrosarcoma, a rare bone cancer with no approved targeted therapies. The drug, which is a DR5-targeting antibody, more than doubled progression-free survival compared to placebo in the ChonDRAgon trial, reducing the risk of disease progression or death by 52%. Inhibrx Biosciences plans to submit a biologics license application (BLA) to the FDA by Q2 2026, aiming to make ozekibart the first targeted therapy for this indication.
Inhibrx eyes FDA submission after phase 2 rare bone cancer win
Inhibrx's antibody ozekibart achieved a significant phase 2 win for advanced or metastatic chondrosarcoma, a rare bone cancer with no approved treatments, by reducing disease progression or death by 52% compared to placebo. This success has prompted the company to plan an FDA submission in Q2 2026. Ozekibart also showed promise in Ewing sarcoma and colorectal cancer in phase 1 cohorts, suggesting broader potential in solid tumor indications.
Inhibrx (NASDAQ: INBX) sets Oct 23 webcast on Ozekibart chondrosarcoma; CRC, Ewing updates
Inhibrx will host a live webcast on October 23, 2025, at 1:30 p.m. PT to present topline results from its registrational ChonDRAgon study of ozekibart (INBRX-109) in chondrosarcoma. The company will also provide updates on ongoing expansion trials investigating ozekibart in colorectal cancer and Ewing sarcoma. Investors can access the webcast or dial in, and the presentation materials will be available on the company's website afterward.
Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment? - simplywall.st
The article analyzes Inhibrx Biosciences' debt levels and overall financial risk. It notes that while the company has increased its debt significantly, it also maintains a net cash position due to substantial cash reserves. Despite this, Inhibrx Biosciences is currently loss-making with declining revenue, suggesting potential future capital raises if profitability isn't achieved soon.
Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment? - simplywall.st
This article analyzes Inhibrx Biosciences' debt and financial risk, noting its increase in debt but also its net cash position. Despite having substantial liquid assets relative to liabilities, the company is currently loss-making with declining revenue, suggesting potential future capital raising needs.
Bullish Inhibrx Biosciences Insiders Rewarded As Their Investment Rises To US$9.02m
Insiders at Inhibrx Biosciences (NASDAQ:INBX) who purchased shares over the past year have seen a 66% return on their investment, with the stock rising 14% and their holdings now valued at US$9.02m. Despite a significant purchase by Independent Director John Kayyem at a lower price point, the overall insider buying trend and current 19% insider ownership suggest alignment with shareholder interests. This bullish activity signals confidence in the company's prospects.
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop
Institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) lost significantly after the stock dropped 15% last week, despite collectively owning 43% of the company. The top 7 shareholders control 50% of the company, with Viking Global Investors LP being the largest at 12%. Insiders have also been buying shares, indicating some confidence in the company's prospects.
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
Inhibrx Biosciences, Inc. announced a decisive legal victory in a trade secrets case brought by I-Mab Biopharma in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation, validating Inhibrx's independent development processes and ethical conduct. This outcome allows Inhibrx to continue focusing on delivering life-changing therapies to patients.
Inhibrx: The Biotech Spinoff Poised For Big Gains
The article highlights Inhibrx, a biotech spinoff, as a hidden gem for investors due to its innovative approach to developing treatments for cancer and rare diseases. CEO Mark Lappe emphasizes the company's agility and focused research, particularly on precision-designed biologics like INBRX-109, which is in late-stage clinical trials. Despite inherent challenges in biotech, Inhibrx's strong pipeline and leadership position it for significant growth and potential breakthroughs.
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Inhibrx Biosciences reported its second quarter 2024 financial results, highlighted by significant income stemming from its separation from the Former Parent and a transaction with Sanofi, totaling approximately $2.2 billion. The company’s net income reached $1.9 billion, or $127.10 per share, compared to a net loss in the prior year, despite increased R&D and G&A expenses due to the separation and ongoing program development. Inhibrx Biosciences continues as a standalone, publicly traded company (Nasdaq: INBX) focusing on its clinical programs, ozekibart (INBRX-109) and INBRX-106.
Sanofi to Acquire Inhibrx Assets for up to $2.2B
Sanofi has announced a definitive agreement to acquire assets related to INBRX-101 from Inhibrx for approximately $2.2 billion. This includes INBRX-101, an alpha-1 antitrypsin (AAT) augmentation therapy. Inhibrx's non-101 discovery pipeline and corporate infrastructure will be spun out into a new company, Inhibrx Biosciences, Inc., led by Inhibrx's current management team, with the acquisition subject to the completion of this spin-off and other closing conditions.
Sanofi to Buy Biotech Firm for $2.2 Billion in Innovation Push
Sanofi has agreed to acquire US biotech firm Inhibrx Inc. for up to $2.2 billion to gain a potential therapy for a rare genetic disorder affecting the lungs and liver. This acquisition is part of Sanofi's strategy to increase its focus on innovative medicines and decrease its dependence on its blockbuster asthma medication, Dupixent. The deal also includes Inhibrx spinning off a new entity with its remaining research and employees.
Sanofi to buy Inhibrx in deal worth up to $2.2B
Sanofi has announced its acquisition of Inhibrx in a complex deal potentially worth up to $2.2 billion. The acquisition's primary focus is Inhibrx's experimental drug INBRX-101 for alpha-1 antitrypsin deficiency, while other Inhibrx assets will be spun out into a new publicly traded company. Sanofi will pay $1.7 billion upfront for Inhibrx equity, with additional funds tied to a contingent value right.
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing
Inhibrx Inc. announced positive topline results from a Phase 1 clinical trial of INBRX-101 for Alpha-1 Antitrypsin Deficiency (AATD), showing a favorable safety profile and potential to achieve normal functional AAT levels with monthly dosing. The drug demonstrated an average functional AAT level of 40.4 µM, significantly higher than the current standard of care and within the normal range observed in healthy individuals, suggesting the potential to reduce infusion frequency from weekly to monthly.
INBX Stock Price and Chart — NASDAQ:INBX
This article provides a detailed overview of Inhibrx Biosciences, Inc. (INBX) stock, including its current price, historical performance over various periods, upcoming earnings information, and key financial statistics such as market capitalization, EPS, and revenue. It also includes company information, related stock ideas, technical analysis, analyst ratings, seasonal trends, and ETF holdings. The content highlights the company's clinical-stage biopharmaceutical operations and its proprietary protein engineering platforms.
